Press Releases Subscribe to our News
04. Oktober 2022
08. September 2022
Regulatory
Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
Release
02. September 2022
Regulatory
Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
Release
31. August 2022
Regulatory
Biosergen publishes interim report for second quarter 2022
ReleaseQ2-2022 Financial Report
26. August 2022
30. Juni 2022
28. Juni 2022
Regulatory
Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB
Release
07. Juni 2022
31. Mai 2022
Regulatory
Biosergen publishes interim report for first quarter 2022
Release2022-Q1 Financial Report
13. Mai 2022
07. April 2022
31. März 2022
Regulatory
Biosergen publishes interim report for fourth quarter 2021
Biosergen Q4 financial report press releaseQ4-2021 Financial Report
30. November 2021
Regulatory
Biosergen publishes interim report for the third quarter 2021
Q3-2021 Financial ReportBiosergen Q3 financial report press release
31. August 2021
Regulatory
Biosergen publishes interim report for the second quarter 2021
Q2-2021 Financial ReportBiosergen Q2 report press release
27. Juni 2021
Regulatory
Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States
Release
08. Juni 2021
